Format

Send to

Choose Destination
Cancer Lett. 2012 Jul 28;320(2):130-7. doi: 10.1016/j.canlet.2012.03.008. Epub 2012 Mar 13.

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.

Author information

1
Oncology Research Unit, Pfizer La Jolla, CA 92121, United States. Farbod.shojaei@pfizer.com

Abstract

It has been nearly 9years since the FDA (Food and Drug Administration) approved the first anti-angiogenic drug (bevacizumab) for treatment of metastatic colorectal cancer. Other angiogenic inhibitors have since been approved or are in different stages of clinical trials. However, continued clinical and preclinical investigations have identified major drawbacks associated with the application of this class of agents, including inherent/acquired resistance and induction of tumor invasiveness. In addition, lack of thoroughly validated predictive biomarkers has been one of the major hurdles to stratify cancer patients and to monitor tumor progression and response to the therapy. Investigations in clinic and preclinical models have provided some molecular and cellular mechanisms for the above challenges. This review aims to provide a concise update from recent findings.

PMID:
22425960
DOI:
10.1016/j.canlet.2012.03.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center